<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROMETHAZINE VC WITH CODEINE - codeine phosphate, promethazine hydrochloride and phenylephrine hydrochloride syrup </strong><br>Dispensing Solutions, Inc.<br></p></div>
<h1>PROMETHAZINE VC WITH CODEINE SYRUP (PROMETHAZINE HYDROCHLORIDE, USP, PHENYLEPHRINE HYDROCHLORIDE, USP AND CODEINE PHOSPHATE, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_43fb0c9e-3742-4264-b27a-2cb4d869407c"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each 5 mL (one teaspoonful), for oral administration contains: Codeine phosphate 10 mg; promethazine hydrochloride 6.25 mg; phenylephrine hydrochloride 5 mg. Alcohol 7%.</p>
<p>Inactive Ingredients: Ascorbic acid, citric acid, D&amp;C Red #33, FD&amp;C Yellow #6, menthol, methylparaben, propylene glycol, propylparaben, purified water, saccharin sodium, sodium benzoate, sodium citrate, strawberry flavor and sucrose.</p>
<p>Codeine is one of the naturally occurring phenanthrene alkaloids of opium derived from the opium poppy; it is classified pharmacologically as a narcotic analgesic. Codeine phosphate may be chemically designated as 7,8-Didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1)(salt) hemihydrate.</p>
<p>The phosphate salt of codeine occurs as white, needle-shaped crystals or white crystalline powder. Codeine phosphate is freely soluble in water and slightly soluble in alcohol. It has a molecular weight of 406.37, a molecular formula of C<span class="Sub">18</span>H<span class="Sub">21</span>NO<span class="Sub">3</span> • H<span class="Sub">3</span>PO<span class="Sub">4</span> • ½H<span class="Sub">2</span>O and the following structural formula:</p>
<div class="Figure"><img alt="This is an image of the structural formula of Codeine." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5c3c2c1b-ab52-410b-8c94-c125c6adb4d2&amp;name=promethvcwithcodeinesyrp-1.jpg"></div>
<p>Promethazine hydrochloride, a phenothiazine derivative, is chemically designated as (±)-10-[2-(Dimethylamino)propyl] phenothiazine monohydrochloride.</p>
<p>Promethazine hydrochloride occurs as a white to <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> yellow, practically odorless, crystalline powder which slowly oxidizes and turns blue on prolonged exposure to air. It is soluble in water and freely soluble in alcohol. It has a molecular weight of 320.88, a molecular formula of C<span class="Sub">17</span>H<span class="Sub">20</span>N<span class="Sub">2</span>S • HCI and the following structural formula:</p>
<div class="Figure"><img alt="This is an image of the structural formula of Promethazine." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5c3c2c1b-ab52-410b-8c94-c125c6adb4d2&amp;name=promethvcwithcodeinesyrp-2.jpg"></div>
<p>Phenylephrine hydrochloride is a sympathomimetic amine salt which is chemically indicated as (-)-<span class="Italics">m</span>-Hydroxy-α-[(methyl-amino)-methyl] benzyl alcohol hydrochloride. It occurs as white or nearly white crystals, having a bitter taste. It is freely soluble in water and alcohol. Phenylephrine hydrochloride is subject to oxidation and must be protected from light and air. It has a molecular weight of 203.67, a molecular formula of C<span class="Sub">9</span>H<span class="Sub">13</span>NO<span class="Sub">2</span> • HCI and the following structural formula:</p>
<div class="Figure"><img alt="This is an image of the structural formula of Phenylephrine." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5c3c2c1b-ab52-410b-8c94-c125c6adb4d2&amp;name=promethvcwithcodeinesyrp-3.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_a198d691-167a-4256-bfc2-3943bf4db033"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_d379520c-81be-46d9-aef9-db46618a297e"></a><a name="section-2.1"></a><p></p>
<h2>Codeine:</h2>
<p class="First">Narcotic analgesics, including codeine, exert their primary effects on the central nervous system and gastrointestinal tract. The <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of codeine are due to its central action; however, the precise sites of action have not been determined, and the mechanisms involved appear to be quite complex. Codeine resembles morphine both structurally and pharmacologically, but its actions at the doses of codeine used therapeutically are milder, with less sedation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and gastrointestinal, urinary and pupillary effects. Codeine produces an increase in biliary tract pressure, but less than morphine or meperidine. Codeine is less constipating than morphine.</p>
<p>Codeine has good antitussive activity, although less than that of morphine at equal doses. It is used in preference to morphine, because side effects are infrequent at the usual antitussive dose of codeine.</p>
<p>Codeine in oral therapeutic dosage does not usually exert major effects on the cardiovascular system. Narcotic analgesics may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> by stimulating the chemoreceptor trigger zone (CTZ); however, they also depress the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> center, so that subsequent doses are unlikely to produce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> is minimal after usual oral doses of codeine.</p>
<p>Narcotic analgesics cause histamine release, which appears to be responsible for <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> sometimes seen at the site of injection on parenteral administration. Histamine release may also produce dilation of cutaneous blood vessels, with resultant <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the face and neck, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
<p>Codeine and its salts are well absorbed following both oral and parenteral administration. Codeine is about ⅔ as effective orally as parenterally. Codeine is metabolized primarily in the liver by enzymes of the endoplasmic reticulum, where it undergoes O-demethylation, N-demethylation and partial conjugation with glucuronic acid. The drug is excreted primarily in the urine, largely as inactive metabolites and small amounts of free and conjugated morphine. Negligible amounts of codeine and its metabolites are found in the feces.</p>
<p>Following oral or subcutaneous administration of codeine, the onset of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> occurs within 15 to 30 minutes and lasts for four to six hours.</p>
<p>The <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>-depressing action, in animal studies, was observed to occur 15 minutes after oral administration of codeine, peak action at 45 to 60 minutes after ingestion. The duration of action, which is dose-dependent, usually did not exceed 3 hours.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_a347ce92-3c01-4143-b7da-fc53354a5c94"></a><a name="section-2.2"></a><p></p>
<h2>Promethazine:</h2>
<p class="First">Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of chlorpromazine) of dopamine antagonist properties.</p>
<p>Promethazine is an H<span class="Sub">1</span> receptor blocking agent. In addition to its antihistaminic action, it provides clinically useful sedative and antiemetic effects.</p>
<p>Promethazine is well absorbed from the gastrointestinal tract. Clinical effects are apparent within 20 minutes after oral administration and generally last four to six hours, although they may persist as long as 12 hours. Promethazine is metabolized by the liver to a variety of compounds; the sulfoxides of promethazine and N-demethylpromethazine are the predominant metabolites appearing in the urine.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_16a719b2-eac3-441d-b15e-61e1851bc70c"></a><a name="section-2.3"></a><p></p>
<h2>Phenylephrine:</h2>
<p class="First">Phenylephrine is a potent postsynaptic-α-receptor agonist with little effect on β receptors of the heart. Phenylephrine has no effect on β-adrenergic receptors of the bronchi or peripheral blood vessels. A direct action at receptors accounts for the greater part of its effects, only a small part being due to its ability to release norepinephrine.</p>
<p>Therapeutic doses of phenylephrine mainly cause <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>. Phenylephrine increases resistance and, to a lesser extent, decreases capacitance of blood vessels. Total peripheral resistance is increased, resulting in increased systolic and diastolic blood pressure. Pulmonary arterial pressure is usually increased, and renal blood flow is usually decreased. Local <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> and hemostasis occur following topical application or infiltration of phenylephrine into tissues.</p>
<p>The main effect of phenylephrine on the heart is <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; it produces a positive inotropic effect on the myocardium in doses greater than those usually used therapeutically. Rarely, the drug may increase the <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> of the heart, causing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">Cardiac output</span> is decreased slightly. Phenylephrine increases the work of the heart by increasing peripheral arterial resistance. Phenylephrine has a mild central stimulant effect.</p>
<p>Following oral administration or topical application of phenylephrine to the mucosa, constriction of blood vessels in the nasal mucosa relieves <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">head colds</span>. Following oral administration, nasal decongestion may occur within 15 or 20 minutes and may persist for up to 4 hours.</p>
<p>Phenylephrine is irregularly absorbed from and readily metabolized in the gastrointestinal tract. Phenylephrine is metabolized in the liver and intestine by monoamine oxidase. The metabolites and their route and rate of excretion have not been identified. The pharmacologic action of phenylephrine is terminated at least partially by uptake of the drug into tissues.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_e8ae1e2d-d277-473d-870c-dc65ed89795e"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Promethazine HCl, phenylephrine HCl and codeine phosphate syrup is indicated for the temporary relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughs</span> and upper respiratory symptoms, including <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_84686d09-538e-4488-80c9-8e1b3aba47bf"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Codeine is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
<p>Promethazine is contraindicated in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines.</p>
<p>The combination of promethazine hydrochloride, phenylephrine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age, because the combination may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in this age population.</p>
<p>Antihistamines and codeine are both contraindicated for use in the treatment of lower respiratory tract symptoms, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Phenylephrine is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or with peripheral <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">vascular insufficiency</span> (<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> may result with risk of <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> of compromised vascular beds). Phenylephrine should not be used in patients known to be hypersensitive to the drug or in those receiving a monoamine oxidase inhibitor (MAOI).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_ed82367d-ce40-40f5-b9e5-18d02da47a20"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="LINK_96975956-3990-41da-a30b-1344b45372b7"></a><a name="section-5.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">WARNING:</span></p>
<p>The combination of promethazine hydrochloride, phenylephrine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age. Concomitant administration of promethazine products with other respiratory depressants has an association with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in pediatric patients.</p>
<p>Postmarketing cases of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, including fatalities, have been reported with use of promethazine hydrochloride in pediatric patients less than 2 years of age. A wide range of weight-based doses of promethazine hydrochloride have resulted in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in these patients.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_8f47f1d2-3539-47b8-a2d7-40607675f356"></a><a name="section-5.1"></a><p></p>
<h2>Codeine:</h2>
<p class="First">Dosage of codeine SHOULD NOT BE INCREASED if <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> fails to respond; an unresponsive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> should be re-evaluated in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease.</p>
<p>Codeine may cause or aggravate <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> leading to arrest, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred with the use of codeine antitussives in young children, particularly in the under-one-year infants whose ability to deactivate the drug is not fully developed.</p>
<p>Administration of codeine may be accompanied by histamine release and should be used with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> children.</p>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_77be02b9-5328-4705-8990-e68c8d2cc217"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> And <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>:</h3>
<p class="First">The respiratory-depressant effects of narcotic analgesics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions, or a preexisting increase in intracranial pressure. Narcotics may produce adverse reactions which may obscure the clinical course of patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_4f4bdbef-6eaa-42ea-a2b3-c8b24713b125"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> And Other Respiratory Conditions:</h3>
<p class="First">Narcotic analgesics or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> suppressants, including codeine, should not be used in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients (see <span class="Bold"><a href="#LINK_84686d09-538e-4488-80c9-8e1b3aba47bf">CONTRAINDICATIONS</a></span>). Nor should they be used in acute febrile illness associated with <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span> or in <span class="product-label-link" type="condition" conceptid="4063381" conceptname="Chronic disease of respiratory system">chronic respiratory disease</span> where interference with ability to clear the tracheobronchial tree of secretions would have a deleterious effect on the patient's respiratory function.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_0d568c98-5a62-486d-b8e7-f2053a14b044"></a><a name="section-5.1.3"></a><p></p>
<h3>Hypotensive Effect:</h3>
<p class="First">Codeine may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_f88e65fc-9151-43d0-9ecc-27614ce3225b"></a><a name="section-5.2"></a><p></p>
<h2>Promethazine:</h2>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_352020b3-de5c-45aa-8901-da56339bd616"></a><a name="section-5.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span> –</h3>
<p class="First">Promethazine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should either be eliminated or given in reduced dosage in the presence of promethazine HCl  (see <span class="Bold"><a href="#LINK_fc4cb436-cb2d-4f68-aa69-f95db1f1591a">PRECAUTIONS - Information For Patients</a></span> and <span class="Bold"><a href="#LINK_0ccb7d80-4aad-4582-b9ca-3d96c200122c">Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_f93c2bc2-7981-4c82-a150-30128ebab4c0"></a><a name="section-5.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> –</h3>
<p class="First">Promethazine may lead to potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>Use of promethazine in patients with compromised respiratory function (e.g., <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>) should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_cb4627c4-5e7d-4aea-9936-494150eb409d"></a><a name="section-5.2.3"></a><p></p>
<h3>Lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Threshold –</h3>
<p class="First">Promethazine may lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. It should be used with caution in persons with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or in persons who are using concomitant medications, such as narcotics or local anesthetics, which may also affect <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_10bd96b6-1690-4f2c-aa2b-e5729737b0a5"></a><a name="section-5.2.4"></a><p></p>
<h3>Bone-<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Marrow Depression</span> –</h3>
<p class="First">Promethazine should be used with caution in patients with bone-<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow depression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported, usually when promethazine HCl has been used in association with other known marrow-toxic agents.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_1e4ab73d-6709-4c10-baf5-c8f721efee1b"></a><a name="section-5.2.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> –</h3>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with promethazine HCl alone or in combination with antipsychotic drugs. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology.</p>
<p>The management of NMS should include 1) immediate discontinuation of promethazine HCl, antipsychotic drugs, if any, and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available.</p>
<p>There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>
<p>Since recurrences of NMS have been reported with phenothiazines, the reintroduction of promethazine HCl should be carefully considered.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_c8015d64-0aed-41d4-b98c-34edcfaa75b2"></a><a name="section-6"></a><p></p>
<h1>Use In Pediatric Patients</h1>
<p class="First"><span class="Bold">The combination of promethazine hydrochloride, phenylephrine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age. Concomitant administration of promethazine products with other respiratory depressants has an association with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in pediatric patients. The association does not directly relate to individualized weight-based dosing, which might otherwise permit safe administration.</span></p>
<p>Excessively large dosages of antihistamines, including promethazine hydrochloride, in pediatric patients may cause <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> (see <span class="Bold"><a href="#LINK_8843bf40-dfbb-482a-81eb-85e4add81ffc">OVERDOSAGE</a></span>). <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have occurred with therapeutic doses and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of promethazine hydrochloride in pediatric patients. In pediatric patients who are acutely ill associated with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, there is an increased susceptibility to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonias</span> with the use of promethazine HCl.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_ccb58432-59a7-4775-8a55-a0479704b4d3"></a><a name="section-7"></a><p></p>
<h1>Other Considerations</h1>
<p class="First">Administration of promethazine has been associated with reported <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_2eecdc1e-af3c-4459-9eaa-4fb0ff9f2f6e"></a><a name="section-8"></a><p></p>
<h1>Phenylephrine:</h1>
<p class="First">Because phenylephrine is an adrenergic agent, it should be given with caution to patients with thyroid diseases, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and heart diseases or those receiving tricyclic antidepressants.</p>
<p>Men with symptomatic, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hypertrophy</span> can experience <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> when given oral nasal decongestants.</p>
<p>Phenylephrine can cause a decrease in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, and extreme caution should be used when administering the drug parenterally or orally to patients with <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>, to elderly individuals and/or to patients with initially poor cerebral or coronary circulation.</p>
<p>Phenylephrine should be used with caution in patients taking diet preparations, such as amphetamines or phenylpropanolamine, because synergistic adrenergic effects could result in serious hypertensive response and possible <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_8e5c841c-718e-40a2-84ca-aa173d05d710"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Animal reproduction studies have not been conducted with the drug combination-promethazine, phenylephrine and codeine. It is not known whether this drug combination can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Promethazine HCl, phenylephrine HCl and codeine phosphate syrup should be given to a pregnant woman only if clearly needed.</p>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_07c3d57b-583a-4dd8-8df8-cad46b17a8cc"></a><a name="section-9.1"></a><p></p>
<h2>General:</h2>
<p class="First">Narcotic analgesics, including codeine, should be administered with caution and the initial dose reduced in patients with acute abdominal conditions, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, significant hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison's disease, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, in patients with recent gastrointestinal or urinary tract surgery and in the very young or elderly or debilitated patients.</p>
<p>Drugs having anticholinergic properties should be used with caution in patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, stenosing <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, pyloroduodenal obstruction, and bladder-neck obstruction.</p>
<p>Promethazine should be used cautiously in persons with cardiovascular disease or with impairment of liver function.</p>
<p>Phenylephrine should be used with caution in patients with cardiovascular disease.</p>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_f842e336-d3a3-4adb-b434-29422598896b"></a><a name="section-9.1.1"></a><p></p>
<h3><span class="Italics">Ultra-Rapid Metabolizers of Codeine</span></h3>
<p class="First">Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2×2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1–10% in Caucasians, 3% in African Americans, and 16–28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.</p>
<p>When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and should inform their patients about these risks and the signs of morphine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (see <span class="Bold"><a href="#LINK_bf93fadc-8358-495a-8e00-2e0a05396fcd">PRECAUTIONS - Nursing Mothers</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_fc4cb436-cb2d-4f68-aa69-f95db1f1591a"></a><a name="section-9.2"></a><p></p>
<h2>Information For Patients:</h2>
<p class="First">Patients should be advised to measure promethazine, phenylephrine and codeine syrup with an accurate measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage, especially when a half a teaspoon is measured. A pharmacist can recommend an appropriate measuring device and can provide instructions for measuring the correct dose.</p>
<p>Promethazine, phenylephrine and codeine may cause marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. Ambulatory patients should be told to avoid engaging in such activities until it is known that they do not become drowsy or dizzy from promethazine, phenylephrine and codeine therapy. The concomitant use of alcohol or other central nervous system depressants, including narcotic analgesics, sedatives, hypnotics and tranquilizers, may have an additive effect and should be avoided or their dosage reduced.</p>
<p>Patients should be advised to report any <span class="product-label-link" type="condition" conceptid="4319906" conceptname="Dyskinesia">involuntary muscle movements</span>.</p>
<p>Avoid prolonged exposure to the sun.</p>
<p>Codeine, like other narcotic analgesics, may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in some ambulatory patients. Patients should be cautioned accordingly.</p>
<p>Caution patients that some people have a variation in a liver enzyme and change codeine into morphine more rapidly and completely than other people. These people are ultra-rapid metabolizers and are more likely to have higher-than-normal levels of morphine in their blood after taking codeine which can result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. In most cases, it is unknown if someone is an ultra-rapid codeine metabolizer.</p>
<p>Nursing mothers taking codeine can also have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Instruct nursing mothers to watch for signs of morphine toxicity in their infants including increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the baby's doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_0ccb7d80-4aad-4582-b9ca-3d96c200122c"></a><a name="section-9.3"></a><p></p>
<h2>Drug Interactions:</h2>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_ceda2b0a-c398-48ee-af26-6dce79abd5c5"></a><a name="section-9.3.1"></a><p></p>
<h3>Codeine:</h3>
<p class="First">In patients receiving MAO inhibitors, an initial small test dose is advisable to allow observation of any excessive narcotic effects or MAOI interaction.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_6f16fc34-2c8d-4470-ace3-baf2ca48bc18"></a><a name="section-9.3.2"></a><p></p>
<h3>Promethazine:</h3>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_6ce81646-264c-4981-8466-50e8ec7bd392"></a><a name="section-9.3.2.1"></a><p></p>
<h4>CNS Depressants –</h4>
<p class="First">Promethazine may increase, prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. When given concomitantly with promethazine, the dose of barbiturates should be reduced by at least one-half, and the dose of narcotics should be reduced by one-quarter to one-half. Dosage must be individualized. Excessive amounts of promethazine HCl relative to a narcotic may lead to <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in the patient with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; these symptoms usually disappear with adequate control of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_ba83d8f3-17c4-4ff4-a13d-2d39f5bf7044"></a><a name="section-9.3.2.2"></a><p></p>
<h4>Epinephrine –</h4>
<p class="First">Because of the potential for promethazine to reverse epinephrine's vasopressor effect, epinephrine should NOT be used to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with promethazine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_a63d2a6f-ee29-4b3f-b8d4-e3066ded2802"></a><a name="section-9.3.2.3"></a><p></p>
<h4>Anticholinergics –</h4>
<p class="First">Concomitant use of other agents with anticholinergic properties should be undertaken with caution.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_254a7cb0-787c-4dd4-80a0-3867a8f27bb0"></a><a name="section-9.3.2.4"></a><p></p>
<h4>Monoamine Oxidase Inhibitors (MAOI) –</h4>
<p class="First">Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_abb4fdf3-09b2-44ab-a230-78d329839685"></a><a name="section-9.3.3"></a><p></p>
<h3>Phenylephrine:</h3>
<a name="i6d63810f-c42d-4f8e-8d83-0704ee3c83b2"></a><table>
<col>
<col>
<col>
<thead><tr class="First Last">
<th> Drug</th>
<th></th>
<th> Effect</th>
</tr></thead>
<tbody>
<tr class="First">
<td> <br>Phenylephrine with prior administration of monoamine oxidase inhibitors (MAOI).</td>
<td> </td>
<td> <br> Cardiac pressor response potentiated. May cause acute <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>.</td>
</tr>
<tr>
<td> <br>Phenylephrine with tricyclic anti-depressants.</td>
<td> </td>
<td> <br> Pressor response increased.</td>
</tr>
<tr>
<td> <br>Phenylephrine with ergot alkaloids.</td>
<td> </td>
<td> <br> Excessive <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>.</td>
</tr>
<tr>
<td> <br>Phenylephrine with bronchodilator sympathomimetic agents and with epinephrine or other sympathomimetics.</td>
<td> </td>
<td>  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> or other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may occur.</td>
</tr>
<tr>
<td> <br>Phenylephrine with prior administration of propranolol or other β-adrenergic blockers.</td>
<td> </td>
<td>  Cardiostimulating effects blocked.</td>
</tr>
<tr>
<td> <br>Phenylephrine with atropine sulfate.</td>
<td> </td>
<td> <br> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Reflex bradycardia</span> blocked; pressor response enhanced.</td>
</tr>
<tr>
<td> <br>Phenylephrine with prior administration of phentolamine or other α-adrenergic blockers.</td>
<td> </td>
<td>  Pressor response decreased.</td>
</tr>
<tr class="Last">
<td> <br>Phenylephrine with diet preparations, such as amphetamines or phenylpropanolamine.</td>
<td> </td>
<td>  Synergistic adrenergic response.</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_66fbc85c-3acd-4a6c-afe7-5cf9669d1c9c"></a><a name="section-9.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<p class="First">Because narcotic analgesics may increase biliary tract pressure, with resultant increases in plasma amylase or lipase levels, determination of these enzyme levels may be unreliable for 24 hours after a narcotic analgesic has been given.</p>
<p>The following laboratory tests may be affected in patients who are receiving therapy with promethazine hydrochloride.</p>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_9a6bfcdc-4530-4dc1-8c5d-1374b521d5d5"></a><a name="section-9.4.1"></a><p></p>
<h3>Pregnancy Tests:</h3>
<p class="First">Diagnostic pregnancy tests based on immunological reactions between HCG and anti-HCG may result in false-negative or false-positive interpretations.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_162f6069-c77b-4fdc-b12f-7791efe7cbe7"></a><a name="section-9.4.2"></a><p></p>
<h3>Glucose Tolerance Test:</h3>
<p class="First">An increase in blood glucose has been reported in patients receiving promethazine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_1b043e50-b0f4-4c48-a7b3-7eb69a25a56d"></a><a name="section-9.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment Of Fertility:</h2>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_3f66492b-ebca-476d-b57c-e7abf6b62c72"></a><a name="section-9.5.1"></a><p></p>
<h3>Codeine And Promethazine:</h3>
<p class="First">Long-term animal studies have not been performed to assess the carcinogenic potential of codeine or of promethazine, nor are there other animal or human data concerning carcinogenicity, mutagenicity, or impairment of fertility with these agents. Codeine has been reported to show no evidence of carcinogenicity or mutagenicity in a variety of test systems, including the micronucleus and sperm abnormality assays and the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>  assay. Promethazine was nonmutagenic in the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>  test system of Ames.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_960908b1-025d-4e39-8cd7-3b0b6a22dc30"></a><a name="section-9.5.2"></a><p></p>
<h3>Phenylephrine:</h3>
<p class="First">A study which followed the development of cancer in 143,574 patients over a four-year period indicated that in 11,981 patients who received phenylephrine (systemic or topical), there was no statistically significant association between the drug and cancer at any or all sites.</p>
<p>Long-term animal studies have not been performed to assess the carcinogenic potential of phenylephrine, nor are there other animal or human data concerning mutagenicity.</p>
<p>A study of the effects of adrenergic drugs on ovum transport in rabbits indicated that treatment with phenylephrine did not alter incidence of pregnancy; the number of implantations was significantly reduced when high doses of the drug were used.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_ba4d7b61-0d3b-4148-b48c-58445b707f97"></a><a name="section-9.6"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_020d879f-93ee-4f6e-b9bd-978e571a25b3"></a><a name="section-9.6.1"></a><p></p>
<h3>Teratogenic Effects –</h3>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_7ab8dd08-a66d-4ae8-9a77-8c1221c9aa7d"></a><a name="section-9.6.1.1"></a><p></p>
<h4>Pregnancy Category C.</h4>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_065e051f-8ea1-486c-bf5f-dff788d57375"></a><a name="section-9.6.1.2"></a><p></p>
<h4>Codeine:</h4>
<p class="First">A study in rats and rabbits reported no teratogenic effect of codeine administered during the period of organogenesis in doses ranging from 5 to 120 mg/kg. In the rat, doses at the 120-mg/kg level, in the toxic range for the adult animal, were associated with an increase in embryo resorption at the time of implantation. In another study a single 100-mg/kg dose of codeine administered to pregnant mice reportedly resulted in delayed ossification in the offspring.</p>
<p>There are no studies in humans, and the significance of these findings to humans, if any, is not known.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_1dc5d826-8ab3-476f-8fe7-5e68bce0dc9b"></a><a name="section-9.6.1.3"></a><p></p>
<h4>Promethazine:</h4>
<p class="First">Teratogenic effects have not been demonstrated in rat-feeding studies at doses of 6.25 and 12.5 mg/kg of promethazine HCl. These doses are from approximately 2.1 to 4.2 times the maximum recommended total daily dose of promethazine for a 50-kg subject, depending upon the indication for which the drug is prescribed. Daily doses of 25 mg/kg intraperitoneally have been found to produce fetal mortality in rats.</p>
<p>Specific studies to test the action of the drug on parturition, lactation, and development of the animal neonate were not done, but a general preliminary study in rats indicated no effect on these parameters. Although antihistamines have been found to produce fetal mortality in rodents, the pharmacological effects of histamine in the rodent do not parallel those in man. There are no adequate and well-controlled studies of promethazine in pregnant women.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_298053c5-965c-4e86-8e61-00ccd09ce8d9"></a><a name="section-9.6.1.4"></a><p></p>
<h4>Phenylephrine:</h4>
<p class="First">A study in rabbits indicated that continued moderate overexposure to phenylephrine (3 mg/day) during the second half of pregnancy (22nd day of gestation to delivery) may contribute to perinatal wastage, <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span>, <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span> and possibly fetal anomalies; when phenylephrine (3 mg/day) was given to rabbits during the first half of pregnancy (3rd day after mating for seven days), a significant number gave birth to litters of low birth weight. Another study showed that phenylephrine was associated with anomalies of aortic arch and with <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span> in the chick embryo.</p>
<p>Promethazine HCl, phenylephrine HCl and codeine phosphate syrup should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_4ab0ebb3-8c74-4eb9-802c-cba652191950"></a><a name="section-9.6.2"></a><p></p>
<h3>Nonteratogenic Effects –</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> has been reported in newborns whose mothers took opiates regularly during pregnancy. Withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Signs usually appear during the first few days of life.</p>
<p>Promethazine administered to a pregnant woman within 2 weeks of delivery may inhibit platelet aggregation in the newborn.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_7111f6c0-0745-4ea1-9557-b92e0f4531f0"></a><a name="section-9.7"></a><p></p>
<h2>Labor And Delivery:</h2>
<p class="First">Narcotic analgesics cross the placental barrier. The closer to delivery and the larger the dose used, the greater the possibility of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn. Narcotic analgesics should be avoided during labor if delivery of a premature infant is anticipated. If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Resuscitation may be required (see <span class="Bold"><a href="#LINK_8843bf40-dfbb-482a-81eb-85e4add81ffc">OVERDOSAGE</a></span>).</p>
<p>Limited data suggest that use of promethazine hydrochloride during labor and delivery does not have an appreciable effect on the duration of labor or delivery and does not increase the risk of need for intervention in the newborn.</p>
<p>The effect of promethazine and/or codeine on later growth and development of the newborn is unknown.</p>
<p>Administration of phenylephrine to patients in late pregnancy or labor may cause fetal <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> by increasing contractility of the uterus and decreasing uterine blood flow.</p>
<p>See also "<a href="#LINK_4ab0ebb3-8c74-4eb9-802c-cba652191950">Nonteratogenic Effects</a>".</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_bf93fadc-8358-495a-8e00-2e0a05396fcd"></a><a name="section-9.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. Despite the common use of codeine products to manage postpartum <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, reports of adverse events in infants are rare. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine's active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in nursing infants.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1–10% in Caucasians, 3% in African Americans, and 16–28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.</p>
<p>The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine-containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. 
								Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding  (see <span class="Bold"><a href="#LINK_f842e336-d3a3-4adb-b434-29422598896b">PRECAUTIONS – General - </a></span><span class="Italics"><a href="#LINK_f842e336-d3a3-4adb-b434-29422598896b">Ultra-Rapid Metabolizers of Codeine</a></span>).</p>
<p>It is not known whether phenylephrine or promethazine are excreted in human milk.</p>
<p>Caution should be exercised when promethazine HCl, phenylephrine HCl and codeine phosphate syrup is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_5f5e831e-2f32-413e-ba06-0eb5c1d6d59c"></a><a name="section-9.9"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First"><span class="Bold">The combination of promethazine hydrochloride, phenylephrine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age, because the combination may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in this age population (</span>see <span class="Bold"><a href="#LINK_96975956-3990-41da-a30b-1344b45372b7">WARNINGS – Black Box Warning</a></span> and <span class="Bold"><a href="#LINK_c8015d64-0aed-41d4-b98c-34edcfaa75b2">Use In Pediatric Patients</a></span><span class="Bold">).</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_2a66bc35-3f89-4ccb-8bb6-1f1cacd44e4f"></a><a name="section-9.10"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies of promethazine hydrochloride, phenylephrine hydrochloride and codeine phosphate syrup did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly; elderly patients generally should be started on low doses of promethazine hydrochloride, phenylephrine hydrochloride and codeine phosphate syrup and observed closely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_7e773156-f99a-4e0c-8960-59c6fd2df492"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Codeine:</span></p>
<p>Nervous System – <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, particularly <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and to a lesser extent circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; light-headedness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, transient <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>Cardiovascular – <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, faintness, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (common to narcotic analgesics).</p>
<p>Gastrointestinal – <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and biliary tract spasm. Patients with chronic <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> may experience increased colonic motility; in patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">acute ulcerative colitis</span>, toxic dilation has been reported.</p>
<p>Genitourinary – <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>; antidiuretic effect has been reported (common to narcotic analgesics).</p>
<p>Allergic – Infrequent <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">giant urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> and <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>.</p>
<p>Other – <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> of the face, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (due to opiate-induced histamine release); <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p><span class="Bold">Promethazine:</span></p>
<p>Central Nervous System – <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> is the most prominent CNS effect of this drug. Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and tongue protrusion; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, excitation, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have also been reported.</p>
<p>Cardiovascular – Increased or decreased blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, faintness.</p>
<p>Dermatologic – <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Hematologic – <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Gastrointestinal – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p>Respiratory – <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (potentially fatal) and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (potentially fatal). (See <span class="Bold"><a href="#LINK_f93c2bc2-7981-4c82-a150-30128ebab4c0">WARNINGS – Promethazine;</a></span><span class="Italics"><a href="#LINK_f93c2bc2-7981-4c82-a150-30128ebab4c0"> <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></span>.)</p>
<p>Other – <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span>. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> (potentially fatal) has also been reported. (See <span class="Bold"><a href="#LINK_1e4ab73d-6709-4c10-baf5-c8f721efee1b">WARNINGS – Promethazine;</a></span><span class="Italics"><a href="#LINK_1e4ab73d-6709-4c10-baf5-c8f721efee1b"> <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a></span>.)</p>
<p>Paradoxical Reactions – <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Hyperexcitability</span> and abnormal movements have been reported in patients following a single administration of promethazine HCI. Consideration should be given to the discontinuation of promethazine HCl and to the use of other drugs if these reactions occur. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> behavior have also been reported in some of these patients.</p>
<p><span class="Bold">Phenylephrine:</span></p>
<p>Nervous System – <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>Cardiovascular – <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (see <span class="Bold"><a href="#LINK_ed82367d-ce40-40f5-b9e5-18d02da47a20">WARNINGS</a></span>).</p>
<p>Other – <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Precordial pain</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_ef1fa089-bcd7-4ae2-805c-2fad32319e3a"></a><a name="section-11"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="LINK_62e5d23b-66e3-456e-bca7-dd5f61665750"></a><a name="section-11.1"></a><p></p>
<h2>Controlled Substance:</h2>
<p class="First">Promethazine HCl, phenylephrine HCl and codeine phosphate syrup is a Schedule V Controlled Substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="LINK_48626ba7-6ee8-4c16-9002-9df49469f1e3"></a><a name="section-11.2"></a><p></p>
<h2>Abuse:</h2>
<p class="First">Codeine is known to be subject to abuse; however, the abuse potential of oral codeine appears to be quite low. Even parenteral codeine does not appear to offer the psychic effects sought by addicts to the same degree as heroin or morphine. However, codeine must be administered only under close supervision to patients with a history of drug abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="LINK_8b5bd8a1-cae4-4f4c-8a3b-ebd002fc6f95"></a><a name="section-11.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>:</h2>
<p class="First">Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance are known to occur with codeine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_8843bf40-dfbb-482a-81eb-85e4add81ffc"></a><a name="section-12"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_41b30cd6-1931-4c62-912b-4de3d9b39a01"></a><a name="section-12.1"></a><p></p>
<h2>Codeine:</h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with codeine is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The triad of <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, pinpoint pupils and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> is strongly suggestive of opiate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. In severe overdosage, particularly by the intravenous route, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. Promethazine is additive to the depressant effects of codeine.</p>
<p>It is difficult to determine what constitutes a standard toxic or lethal dose. However, the lethal oral dose of codeine in an adult is reported to be in the range of 0.5 to 1.0 gram. Infants and children are believed to be relatively more sensitive to opiates on a body-weight basis. Elderly patients are also comparatively intolerant to opiates.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_ea7d86b0-a64f-4b43-8a25-e61ccd0444e0"></a><a name="section-12.2"></a><p></p>
<h2>Promethazine:</h2>
<p class="First">Signs and symptoms of overdosage with promethazine HCl range from mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system and cardiovascular system to profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Other reported reactions include <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>, and extensor-plantar reflexes (Babinski reflex).</p>
<p>Stimulation may be evident, especially in children and geriatric patients. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may rarely occur. A paradoxical reaction has been reported in children receiving single doses of 75 mg to 125 mg orally, characterized by <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>.</p>
<p>Atropine-like signs and symptoms – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, fixed, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, as well as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, may occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_d06c8416-14bf-4a2c-afd6-8d7155a2d87c"></a><a name="section-12.3"></a><p></p>
<h2>Phenylephrine:</h2>
<p class="First">Signs and symptoms of overdosage with phenylephrine include <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Ventricular <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span> and short paroxysms of <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> may also occur. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> may be a symptom of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> may also be seen early in phenylephrine overdosage through stimulation of baroreceptors.</p>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_c6bdad6e-e6fb-435b-98d6-c6ecea4b6da9"></a><a name="section-12.3.1"></a><p></p>
<h3><span class="Bold">Treatment:</span></h3>
<p class="First">The treatment of overdosage with promethazine, phenylephrine and codeine is essentially symptomatic and supportive. Only in cases of extreme overdosage or individual sensitivity do vital signs including respiration, pulse, blood pressure, temperature and EKG need to be monitored. Activated charcoal orally or by lavage may be given, or sodium or magnesium sulfate orally as a cathartic. Attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. The narcotic antagonist, naloxone hydrochloride, may be administered when significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs with promethazine, phenylephrine and codeine; any depressant effects of promethazine are not reversed with naloxone. Diazepam may be used to control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Avoid analeptics, which may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> and electrolyte losses should be corrected. A rise in temperature or pulmonary complications may signal the need for institution of antibiotic therapy.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually responds to the administration of norepinephrine or phenylephrine. EPINEPHRINE SHOULD NOT BE USED, since its use in a patient with partial adrenergic blockade may further lower the blood pressure.</p>
<p>Limited experience with dialysis indicates that it is not helpful.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_13bf2e98-b3c6-475b-9bc2-149bb3b389b4"></a><a name="section-13"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">The combination of promethazine hydrochloride, phenylephrine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age, because the combination may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in this age population.</span></p>
<p>It is important that promethazine hydrochloride, phenylephrine hydrochloride and codeine phosphate syrup is measured with an accurate measuring device (see <span class="Bold"><a href="#LINK_fc4cb436-cb2d-4f68-aa69-f95db1f1591a">PRECAUTIONS-Information For Patients</a></span>). A household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is to be measured. It is strongly recommended that an accurate measuring device be used. A pharmacist can provide an appropriate device and can provide instructions for measuring the correct dose.</p>
<p>The average effective dose for adults and children 12 years of age and over is 1 teaspoonful (5 mL) every 4 to 6 hours, not to exceed 30 mL in 24 hours.</p>
<p>The average effective dose for children 6 years to under 12 years of age is ½ to 1 teaspoonful (2.5 mL to 5 mL) every 4 to 6 hours, not to exceed 30 mL in 24 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_01b820b2-faaf-44f6-a4ad-a6aa84939a04"></a><a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Each 5 mL of reddish-clear syrup with odor of strawberry menthol contains promethazine hydrochloride 6.25 mg, phenylephrine hydrochloride 5 mg, codeine phosphate 10 mg; and alcohol 7% and is available in 4 fluid ounce (118 mL), 8 fluid ounce (237 mL), and one pint (473 mL).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_b508ae33-e6fd-4b38-a1ab-319d6ad9844a"></a><a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First">Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container with a child-resistant closure as defined in the USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bb0fa3c2-6525-4072-8c19-20cb8c9f9c44"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br><span class="Bold">QUALITEST PHARMACEUTICALS</span><br>Huntsville, AL 35811</p>
<p>8181659<br>R1/09-R4</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_814b1eb9-51ae-4e92-80f5-9920e0b4dfe6"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<br><div class="Figure"><img alt="NDC 55045-1266-08" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5c3c2c1b-ab52-410b-8c94-c125c6adb4d2&amp;name=NDC%2055045-1266-08------Qualitest%20Pharmaceuticals.jpg"></div>
<br>NDC 55045-1266-08<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETHAZINE VC WITH CODEINE 		
					</strong><br><span class="contentTableReg">codeine phosphate, promethazine hydrochloride, and phenylephrine hydrochloride syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55045-1266(NDC:0603-1588)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CODEINE PHOSPHATE</strong> (CODEINE) </td>
<td class="formItem">CODEINE PHOSPHATE</td>
<td class="formItem">10 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">6.5 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENYLEPHRINE HYDROCHLORIDE</strong> (PHENYLEPHRINE) </td>
<td class="formItem">PHENYLEPHRINE HYDROCHLORIDE</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASCORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MENTHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red (Clear-Reddish) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55045-1266-8</td>
<td class="formItem">118 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040660</td>
<td class="formItem">12/07/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dispensing Solutions, Inc.
							(066070785)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dispensing Solutions, Inc.</td>
<td class="formItem"></td>
<td class="formItem">066070785</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e3562eaf-3ea6-4b11-903d-43479c7a1f1a</div>
<div>Set id: 5c3c2c1b-ab52-410b-8c94-c125c6adb4d2</div>
<div>Version: 1</div>
<div>Effective Time: 20111007</div>
</div>
</div> <div class="DistributorName">Dispensing Solutions, Inc.</div></p>
</body></html>
